ArticleEpilepsia open2026
Cost-effectiveness of laser interstitial thermal therapy vs. anterior temporal lobectomy for drug-resistant mesial temporal lobe epilepsy: A decision analytic model.
Article in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo evaluate the comparative cost-effectiveness of anterior temporal lobectomy (ATL) and magnetic resonance-guided laser interstitial thermal therapy (LITT) in patients with drug-resistant mesial temporal lobe epilepsy (mTLE).
methodsA decision-analytic model was constructed to simulate the risks, benefits, and costs of ATL versus LITT over a 1-year time horizon from a healthcare system perspective. Model inputs, including seizure freedom rates, complication probabilities, and cost estimates, were derived from recent meta-analyses and published cost comparison studies. The main outcome measure was the probability of a positive outcome, which was defined as seizure freedom without major complication. Incremental cost-effectiveness ratios (ICERs) were calculated, and both one-way and two-way sensitivity analyses were conducted to assess parameter uncertainty.
resultsIn the base-case analysis, ATL achieved a 61% probability of a positive outcome compared with 55% for LITT. The mean per-patient cost was $145 847 for ATL and $108 730 for LITT, resulting in an incremental cost of $37 117. Although ATL provided a modest 6% absolute increase in favorable outcomes, the ICER was $574 521 per additional positive outcome gained relative to LITT. Sensitivity analyses demonstrated that LITT remained the more cost-effective option under most plausible parameter values, with ATL becoming favorable only under conditions of unusually high seizure freedom and low complication rates. SIGNIFICANCE: Although ATL yields slightly superior seizure outcomes, its substantially higher costs render LITT the more cost-effective strategy for drug-resistant mTLE at a 1-year horizon. These findings support the growing role of minimally invasive techniques in epilepsy surgery, though further real-world and long-term data are needed to confirm the durability of LITT's clinical and economic benefits. PLAIN LANGUAGE SUMMARY: This study compared two surgical treatments for drug-resistant mesial temporal lobe epilepsy: anterior temporal lobectomy (ATL) and laser interstitial thermal therapy (LITT). Using a decision-analytic model over 1 year, ATL showed slightly better seizure outcomes but at a substantially higher cost. Overall, LITT was more cost-effective in most scenarios due to lower costs and fewer complications. These findings suggest that LITT may offer a practical and economically favorable option for many patients, although treatment decisions should still consider individual clinical factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.